Keywords: IL15 Cytokine Brain Immunity Autoimmune disease Blood-brain barrier Interleukin (IL)-15 can cross the blood-brain barrier to act on its specific brain receptor (IL15Rα) and coreceptors. The important roles of neuronal IL15 and IL15Rα in experimental autoimmune encephalomeylitis (EAE) are suggested by the upregulation of IL15Rα mRNA in different regions of the brain and spinal cord, and by double-labeling immunohistochemistry showing neuronal localization of IL15 and IL15Rα in different neurons. Contrary to expectations, IL15 treatment lessened EAE severity. IL15 knockout mice showed heightened susceptibility to EAE with significantly higher scores that were decreased by treatment with IL15. Thus, IL15 improves this CNS autoimmune disorder as a potential therapeutic agent.
Introduction
Experimental autoimmune encephalomyelitis (EAE) reflects the autoimmune aspect of the human disease multiple sclerosis (MS), a devastating demyelinating disorder of the central nervous system (CNS) (Hart et al., 1998; 't Hart and Amor, 2003) . Despite the use of disease modifying agents including β interferons, glatiramer, mitoxantrone, and newer immunomodulatory agents, the prognosis remains poor for the relapsing-remitting and primary progressive types of MS. This warrants better understanding of its neuropathology and the search for novel therapeutic agents. Although proinflammatory cytokines play important roles in the progression of MS (Merrill et al., 1984; Zozulya et al., 2009 ), very few studies have directly addressed the role of interleukin (IL)-15 in MS and EAE. Here, we tested the hypotheses that the cerebral IL15 system is regulated by EAE and that it in turn modifies the severity of EAE.
IL15 is a 14 kD polypeptide that belongs to the IL2 subfamily of the four-alpha-helix bundle family of cytokines. IL15 binds to its specific receptor IL15Rα and two additional receptor subunits -IL2Rβ and IL2Rγ. IL15 mRNA has been found to be constitutively expressed in parenchymal cells of many organs as well as immune cells. In the nervous system, IL15 is expressed by neurons, astrocytes, and microglia (Lee et al., 1996; Budagian et al., 2006) . Elevated expression of IL15 at both transcriptional and translational levels is found in peripheral blood mononuclear cells from MS patients (Pashenkov et al., 1999; BlancoJerez et al., 2002) . Furthermore, upregulated IL15 is observed in serum and cerebrospinal fluid of MS patients (Losy et al., 2002; Rentzos et al., 2006) . We have recently shown that EAE affects the distribution and turnover of IL15 after intravenous delivery which also alters the in-vivo BBB permeability to IL15 (Hsuchou et al., 2009b) . This provides a basis to determine the functional roles of the IL15 system in EAE.
EAE is an ascending disease with a maximal increase in the permeability of the blood-brain and blood-spinal cord barrier (BBB) occurring in the lumbar and cervical spinal cord (Pan et al., 1996) . Disruption of the BBB and demyelination are also pronounced in the brain. Although many EAE studies focused on neuropathology in the spinal cord, cerebral involvement probably has greater correlation with sickness behavior. In human MS, there is a higher incidence of supratentorial lesions than spinal cord demyelination. Therefore, the hippocampus was chosen as a region of interest for the study of EAE, since its susceptibility to neuroinflammation and corresponding behavioral changes have been well characterized (Pollak et al., 2002; Goshen et al., 2007; Dantzer et al., 2008) . In this study, we determined both regulatory changes of the endogenous IL15 system and treatment effects of IL15. Further, the exciting finding that IL15 knockout (KO) mice show heightened susceptibility to EAE strongly supports an immunoprotective role of IL15 in EAE mice.
Materials and methods

Induction of EAE and IL15 treatment
All studies were conducted following a protocol approved by the Institutional Animal Care and Use Committee. EAE was induced in Journal of Neuroimmunology 223 (2010) [65] [66] [67] [68] [69] [70] [71] [72] 
